Progress towards a Group B streptococcal vaccine - where are we now?

Area of Science:

• Obstetrics and Gynecology
• Vaccinology
• Infectious Diseases

Background:

• Group B Streptococcus (GBS) poses a significant global health threat, particularly to newborns.
• Despite decades of research, an effective GBS vaccine for pregnant individuals remains an unmet public health need.
• Previous vaccine development efforts demonstrated immunogenicity and safety but did not yield a licensed product.

Purpose of the Study:

• To review the current progress in the development of a Group B Streptococcus (GBS) vaccine.
• To identify and discuss the challenges hindering the licensure of a GBS vaccine.
• To explore potential strategies for overcoming these obstacles in GBS vaccine development.

Main Methods:

• Review of historical and recent scientific literature on GBS vaccine development.
• Analysis of clinical trial data for GBS vaccine candidates.
• Examination of regulatory pathways and public health requirements for vaccine approval.

Main Results:

• Two GBS vaccine candidates have advanced to late-stage clinical development.
• Evidence of immunogenicity and safety has been established in earlier GBS vaccine research.
• Significant challenges persist in achieving a fully licensed and globally accessible GBS vaccine.

Conclusions:

• Continued research and development are essential for a successful GBS vaccine.
• Addressing developmental and regulatory hurdles is critical for meeting the public health need for a GBS vaccine.
• Overcoming current challenges may involve novel approaches to vaccine design and implementation strategies.